The only

IV SAFETY SOLUTION

to reduce avoidable harm, risk, and drive cost savings

ivWatch FDA-cleared & CE-marked technology addresses the biggest underreported patient harm event in healthcare.

By continuously monitoring a patient's IV site, ivWatch detects early signs of infiltration and extravasation—often long before any visual or physical symptoms appear.

ivWatch®

Continuous Monitoring Sensor

The Harm

53%

of IV infiltrations result in severe injuries

The Solution

93%

reduction in severe events with ivWatch implemented [1]

Cross section under the skin of the IV site with ivWatch technology

1. van Rens MFPT, Hugill K, van der Lee R, Francia ALV, van Loon FHJ, Bayoumi MAA. Evaluation of optical sensor technology for the early detection of peripheral intravenous infiltration in neonates: a retrospective cohort study. Pediatrics. 2025;Volume 15 (Issue7).

IVWATCH TECHNOLOGY

is approved globally for any:

- body mass
- skin tone
- age group
- peripheral IV site

For high accuracy results, the sensor takes optical measurements **5X** every second.

ivWatch has a proven record of detecting IV infiltrations a median of **15 HOURS** before the clinician.[2]



2. Doellman, D. and Rineair, S. (2019) The use of optical detection for continuous monitoring of pediatric IV sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.

IV THERAPY DANGERS

IV infiltrations and extravasations can cause severe injuries. These painful results and suffering are preventable.

- Medication dosing errors
- Skin necrosis & skin staining
- Scaring
- Nerve damage
- Amputation

Issued notifications for **99.0%** of early-stage infiltrations of **10 mL** or less.[3,4]

95% Confidence Interval: 94.5 to 100%

97/98 Infiltrations Detected

Detects infiltrations in as little as 0.2 mL of IV fluid, with an average detection volume of **2.02 mL**.[3]



3. ivWatch, LLC. (2019). ivWatch SmartTouchTM Sensor: Device validation for infiltrated tissues. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04064229.

4. ivWatch, LLC. (2019). ivWatch SmartTouchTM Sensor: Device Validation for Non-Infiltrated Tissues. ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT04065373.

REDUCE IV INJURIES & MITIGATE RISK BEFORE HARM IS DONE

Reduced total cost of risk

Fewer judgments, lower cost judgments, lower legal costs, and lower insurance premiums

Reduced uncompensated remedial care

Lower costs through avoided bed days and remedial procedures such as skin grafts, wound debridement, and amputations

Improve patient satisfaction

Higher revenues driven by higher patient satisfaction due to lower severe complication rates

Scan to see how ivWatch technology works or visit:
ivWatch.com
1-855-489-2824

DM-1002375 Rev.03